Preclinical Biosciences
Our unique 'First in Man-enabling' drug development program is based on ICH Guidelines, and includes the mandatory core battery of toxicology and safety pharmacology evaluations, providing the perfect solution for some of of our smaller innovators in reaching early candidate selection decisions


Printer Friendly Text Only Page
Blue underline

Preclinical Biosciences

In order to develop a novel compound to become a safe and effective treatment, a package of studies is required. Often these study designs need to be tailored for each compound in development. This requirement is partnered with the need for accurate assessment of safety data, confidence in this data, and often requires delivery within tight timescales.

Aptuit’s Preclinical Biosciences group has the know-how and experience to design and execute all of these study requirements from a single source. More importantly, they have the experience and the confidence in their data to provide an accurate and balanced assessment of preclinical safety, even when these studies are on tight timelines.

This expertise is further enhanced with the support and experience of our Consulting and Project Management teams, ensuring your product moves beyond preclinical regulatory requirements, getting a significant head start to proof of concept and beyond.

Aptuit recognizes the important steps involved in taking a pharmaceutical new chemical entity from drug discovery through to IND submission and first in man dosing. Our pharmacology services provide early-stage efficacy evaluations to aid candidate selection. Our approach to evaluate early a biological target through the eyes of a toxicologist (Early Safety Prediction) and to raise early possible structure related effects of a molecule (Computational Toxicology), adds robustness to the discovery process. Our unique ‘First in Man-enabling’ fully integrated drug-development program provides the mandatory core battery of safety studies, and also a series of recommended in vitro drug metabolism studies to enhance understanding of the pharmacokinetic profile and metabolism.

Emerging Drug Technologies

Other families of compounds (e.g. biologics) or indications (e.g. oncology) warrant different strategies. Taking advantage of our immunology expertise and immunoassay platform, we are in the ideal position to support projects in biologics area. Moreover, thanks to our strong molecular expertise, we can perform the preclinical safety evaluation of gene therapy studies.

Our full complement of technologies includes:

Related Case Studies
Related Factsheets
Ask an Expert
Our experts are at your disposal - if you have a question related to your drug development programme our experts may be able to help.

We have dedicated experts across all of our service lines. Simply fill out the form below.

CAB Member Login

The information in this section of our website is reserved for Client Advisory Board members.

If you require or have misplaced a password, please click here.